JP2013541582A5 - - Google Patents

Download PDF

Info

Publication number
JP2013541582A5
JP2013541582A5 JP2013537287A JP2013537287A JP2013541582A5 JP 2013541582 A5 JP2013541582 A5 JP 2013541582A5 JP 2013537287 A JP2013537287 A JP 2013537287A JP 2013537287 A JP2013537287 A JP 2013537287A JP 2013541582 A5 JP2013541582 A5 JP 2013541582A5
Authority
JP
Japan
Prior art keywords
adhd
pharmaceutically acceptable
lurasidone
acid addition
acceptable acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013537287A
Other languages
English (en)
Japanese (ja)
Other versions
JP5855670B2 (ja
JP2013541582A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2013537287A priority Critical patent/JP5855670B2/ja
Priority claimed from PCT/JP2011/062314 external-priority patent/WO2012063513A1/en
Publication of JP2013541582A publication Critical patent/JP2013541582A/ja
Publication of JP2013541582A5 publication Critical patent/JP2013541582A5/ja
Application granted granted Critical
Publication of JP5855670B2 publication Critical patent/JP5855670B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013537287A 2010-11-08 2011-05-24 精神疾患の治療方法 Active JP5855670B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013537287A JP5855670B2 (ja) 2010-11-08 2011-05-24 精神疾患の治療方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41108110P 2010-11-08 2010-11-08
US61/411,081 2010-11-08
JP2011033453 2011-02-18
JP2011033453 2011-02-18
PCT/JP2011/062314 WO2012063513A1 (en) 2010-11-08 2011-05-24 Method of treatment for mental disorders
JP2013537287A JP5855670B2 (ja) 2010-11-08 2011-05-24 精神疾患の治療方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015240067A Division JP6470164B2 (ja) 2010-11-08 2015-12-09 精神疾患の治療方法

Publications (3)

Publication Number Publication Date
JP2013541582A JP2013541582A (ja) 2013-11-14
JP2013541582A5 true JP2013541582A5 (enExample) 2014-07-10
JP5855670B2 JP5855670B2 (ja) 2016-02-09

Family

ID=46020227

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537287A Active JP5855670B2 (ja) 2010-11-08 2011-05-24 精神疾患の治療方法
JP2015240067A Active JP6470164B2 (ja) 2010-11-08 2015-12-09 精神疾患の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015240067A Active JP6470164B2 (ja) 2010-11-08 2015-12-09 精神疾患の治療方法

Country Status (6)

Country Link
US (5) US8258139B2 (enExample)
EP (1) EP2638038A4 (enExample)
JP (2) JP5855670B2 (enExample)
CN (1) CN103180315A (enExample)
CA (1) CA2814828C (enExample)
WO (1) WO2012063513A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103565776A (zh) * 2012-07-25 2014-02-12 天津市汉康医药生物技术有限公司 一种稳定的鲁拉西酮胶囊药物组合物
WO2014192868A1 (ja) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 環状アミノメチルピリミジン誘導体
US10272080B2 (en) 2013-09-13 2019-04-30 Florida State University Research Foundation, Inc. Selective dopamine D4 receptor agonists for treatment of working memory deficits
JP6594351B2 (ja) 2014-06-16 2019-10-23 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 新規中間体を含むアルキル化アリールピペラジン及びアルキル化アリールピペリジン化合物の製造方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
DK36291D0 (da) 1991-03-01 1991-03-01 Lundbeck & Co As H Anvendelse af piperidylsubstituerede indolderivater til behandling af kognitive lidelser
GB9202915D0 (en) 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
IL110011A (en) 1994-06-13 2004-09-27 Yeda Res & Dev Pharmacological preparations for the treatment of schizophrenia
WO1996014297A1 (en) 1994-11-04 1996-05-17 Sumitomo Pharmaceuticals Company, Limited Novel lactam derivatives
JP3775823B2 (ja) 1995-06-09 2006-05-17 大日本住友製薬株式会社 新規なイミド誘導体
US5688798A (en) 1995-10-10 1997-11-18 Hoffmann-La Roche Inc. Pyrimidine compounds
PT1073432E (pt) 1998-04-14 2007-10-22 Gen Hospital Corp Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia
JP2000281576A (ja) 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd イミド誘導体を含有するプロテオグリカン生成促進剤
AR027134A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de indol.
JP2004518628A (ja) 2000-09-14 2004-06-24 グリアテック インコーポレイテッド 窒素含有化合物およびそれらのグリシン輸送阻害薬としての使用法
EP1327440B1 (en) 2000-09-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Oral preparations with favorable disintegration characteristics
MXPA03006003A (es) 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
US7067507B2 (en) 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
JP4568463B2 (ja) 2001-11-05 2010-10-27 独立行政法人科学技術振興機構 ドレブリンa発現抑制動物神経細胞及び非ヒトモデル動物
JP4175800B2 (ja) 2001-11-27 2008-11-05 住友化学株式会社 イミド誘導体の製造方法
JP2006505489A (ja) 2002-02-08 2006-02-16 アボット・ラボラトリーズ 精神分裂病の治療のための併用療法
ATE431147T1 (de) 2002-08-22 2009-05-15 Dainippon Sumitomo Pharma Co Mittel zur behandlung des integrationsdysfunktionssyndroms
CA2531980C (en) 2003-06-23 2013-09-17 Dainippon Sumitomo Pharma Co., Ltd. Imide derivatives as therapeutic agents for senile dementia
EP1726952A4 (en) 2004-02-20 2008-06-18 Dainippon Sumitomo Pharma Co METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA
US7122683B2 (en) * 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
ES2390353T3 (es) * 2005-06-13 2012-11-12 Dainippon Sumitomo Pharma Co., Ltd. Preparación de disolución
TW200812993A (en) 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
US7662820B2 (en) 2006-10-30 2010-02-16 Sanrx Pharmaceuticals, Inc. Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon
AU2008236705B2 (en) * 2007-04-04 2014-01-23 Merck Sharp & Dohme Corp. Therapeutic agents
JP2008135074A (ja) 2008-02-25 2008-06-12 Fujitsu Ltd 情報公開方法および情報公開装置

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
JP2012255026A5 (enExample)
JP2010529118A5 (enExample)
JP2014528474A5 (enExample)
JP2013525444A5 (enExample)
JP2013509429A5 (enExample)
JP2014521735A5 (enExample)
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
JP2013507415A5 (enExample)
JP2016517888A5 (enExample)
JP2013518107A5 (enExample)
BR112012003283A8 (pt) sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, composição farmacêutica, produto, kit, uso de um sal farmaceuticamente aceitável de um agente fotossensibilizante anfifílico, e, método de introdução de uma molécula de medicamento no citosol de uma célula em um paciente.
JP2013541583A5 (enExample)
MX343620B (es) Forma polimorfica de clorhidrato de pridopidina.
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2012519182A5 (enExample)
MD4369B1 (ro) Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei
CY1119597T1 (el) Συνθεσεις και μεθοδοι για υπερκεραση αντοχης σε τραμαδολη
JP2014512355A5 (enExample)
JP2012504560A5 (enExample)
JP2015516419A5 (enExample)
JP2013541582A5 (enExample)